[Federal Register Volume 63, Number 131 (Thursday, July 9, 1998)]
[Notices]
[Pages 37137-37138]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-18290]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By notice dated January 21, 1998, and published in the Federal 
Register on February 12, 1998 (63 FR 7181), Johnson & Johnson 
Pharmaceutical Partners, HC-02 Box 19250, KMO.1 Mamey Ward (HC-02 Box 
19250), Gurabo, Puerto Rico 00778-9629, made application by renewal to 
the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of sufentanil (9740), a basic class of controlled 
substance listed in schedule II.
    The firm plans to manufacture sufentanil for bulk distribution to 
its customers.
    DEA has considered the factors in Title 21, United States Code, 
Section 823(a) and determined that the registration of Johnson & 
Johnson Pharmaceutical Partners to manufacture sufentanil is consistent 
with the public interest at this time. Therefore, pursuant

[[Page 37138]]

to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant 
Administrator, Office of Diversion Control, hereby orders that the 
application submitted by the above firm for registration as a bulk 
manufacturer of the basic class of controlled substance listed above is 
granted.

    Dated: June 30, 1998.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 98-18290 Filed 7-8-98; 8:45 am]
BILLING CODE 4410-09-M